Cargando…

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome

Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal antibodies as well as anti-tumor necrosis factor are considered promising treatments for COVID-19. A prospective cohort study in which patients are divided into three groups. Group 1: moderate and severe COVID-19 patients re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarhan, Neven Mohamed, Warda, Ahmed Essam Abou, Ibrahim, Haytham Soliman Ghareeb, Schaalan, Mona Farag, Fathy, Shaimaa Mohamed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116445/ https://www.ncbi.nlm.nih.gov/pubmed/37081046 http://dx.doi.org/10.1038/s41598-023-33484-6

Ejemplares similares

Pentoxifylline Effects on Hospitalized COVID-19 Patients with Cytokine Storm Syndrome: A Randomized Clinical Trial
por: Sarhan, Rania M., et al.
Publicado: (2023)

Evidence for the Efficacy of a High Dose of Vitamin D on the Hyperinflammation State in Moderate-to-Severe COVID-19 Patients: A Randomized Clinical Trial
por: Sarhan, Neven, et al.
Publicado: (2022)

Can tocilizumab calm the cytokine storm of COVID-19?
por: Schulert, Grant S
Publicado: (2020)

Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients
por: Sarhan, Rania M., et al.
Publicado: (2022)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

The Impact of Sociodemographic, Nutritional, and Health Factors on the Incidence and Complications of COVID-19 in Egypt: A Cross-Sectional Study
por: Schaalan, Mona, et al.
Publicado: (2022)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
por: Langer-Gould, Annette, et al.
Publicado: (2020)

Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19
por: Saha, Abinit, et al.
Publicado: (2020)

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
por: Antinori, Spinello, et al.
Publicado: (2020)

Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome
por: Oliynyk, Oleksandr, et al.
Publicado: (2021)

A Neonate With Cytokine Storm Managed With Steroids, Therapeutic Plasma Exchange, and Tocilizumab
por: LiKamWa, Amy, et al.
Publicado: (2023)

Role of Tocilizumab in the Treatment of COVID-19 Patients with Cytokine Storm: A Case Series
por: Basnet, Ajaya, et al.
Publicado: (2022)

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
por: Pelaia, Corrado, et al.
Publicado: (2021)

Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers
por: Nasa, Prashant, et al.
Publicado: (2020)

Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report
por: Chitturi, Kalyan R, et al.
Publicado: (2020)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

Comparison of Rheumatoid Arthritis Patients’ 2-Year Infliximab, Abatacept, and Tocilizumab Persistence Rates
por: Diep, Laetitia, et al.
Publicado: (2022)

The Use of Single Therapy With Tocilizumab Versus Combination Therapy With Remdesivir and Tocilizumab in SARS-CoV-2 Patients in El Paso, Texas
por: Almaghlouth, Nouf K, et al.
Publicado: (2021)

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care
por: Quartuccio, Luca, et al.
Publicado: (2020)

Correction: Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
Publicado: (2019)

Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab
por: Mori, Shunsuke, et al.
Publicado: (2011)

Retention rates of infliximab and tocilizumab during a 3-year period in a Brazilian hospital
por: Golmia, Ricardo Prado, et al.
Publicado: (2013)

Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm
por: Guo, Chuang, et al.
Publicado: (2020)

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study
por: Ramiro, Sofia, et al.
Publicado: (2020)

The effect of tocilizumab on cytokine release syndrome in COVID-19 patients
por: de Cáceres, Carmen, et al.
Publicado: (2020)

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
por: Hassoun, Ali, et al.
Publicado: (2020)

Effect of Pirfenidone on Risk of Pulmonary Fibrosis in COVID-19 Patients Experiencing Cytokine Storm
por: Boshra, Marian S., et al.
Publicado: (2022)

Impact of Vitamin D Supplementation on the Clinical Outcomes and Epigenetic Markers in Patients with Acute Coronary Syndrome
por: Sarhan, Neven, et al.
Publicado: (2023)

Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection
por: Rabie, Al Shaimaa Ibrahim, et al.
Publicado: (2023)

Tocilizumab, an IL6-receptor antibody, proved effective as adjuvant therapy for cytokine storm induced by severe infection in patients with hematologic malignancy
por: Wang, Bingjie, et al.
Publicado: (2023)

Tocilizumab and COVID-19
por: Chaudhry, Dhruva, et al.
Publicado: (2020)

Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
por: Burmester, Gerd R, et al.
Publicado: (2016)

Efficacy of Tocilizumab in Management of COVID-19 Patients Admitted to Intensive Care Units: A Multicenter Retrospective Cohort Study
por: Ibrahem, Hoda Younes, et al.
Publicado: (2022)

Tocilizumab‐induced cytomegalovirus colitis in a patient with COVID‐19
por: Khatib, Mohamad Y., et al.
Publicado: (2020)

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
por: Uslu, Sadettin
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy
por: Lebedeva, Anna, et al.
Publicado: (2022)

Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia—A Retrospective Study
por: Chober, Daniel, et al.
Publicado: (2022)

Effects of Long-Term Methotrexate, Infliximab, and Tocilizumab Administration on Bone Microarchitecture and Tendon Morphology in Healthy Wistar Rats
por: Poutoglidou, Frideriki, et al.
Publicado: (2021)

Comparative Evaluation of Sildenafil Citrate and Estrogen as an Adjuvant Therapy for Treatment of Unexplained Infertility in Women
por: Altyar, Ahmed E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ucgrar7fo30vmdb9kvl7uujthf